Last Price$8.511.2%
Market Cap$1,347.5M
LTM PEG 1Y
16.3x
5Y avg
19.8x
Biotechnology industry
median
0.0x
Stock quality & Intrinsic value
6/10
0.1% undervalued
Ocular Therapeutix, Inc. PEG 1Y
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PEG 1Y | 39.9x | 13.0x | 10.0x | 4.3x | 6.2x | 5.0x | 30.4x | 12.3x | 7.7x | 11.0x | 16.3x |
Overvalued or undervalued?
Check the intrinsic value for OCUL
and see if it's the right time to invest.
Ocular Therapeutix, Inc. (OCUL) PEG 1Y comparison analysis
General
LTM PEG 1Y
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Ocular Therapeutix, Inc.OCUL
14.2x
9.0%
11.9%
(303.7%)
Median Peer Set
0.4x
14.8%
(19.3%)
7.5%
Regeneron Pharmaceuticals, Inc.REGN
5.6x
8.3%
10.4%
31.1%
Alnylam Pharmaceuticals, Inc.ALNY
4.2x
23.0%
(38.6%)
(12.4%)
argenx SEARGX
2.5x
198.6%
(60.5%)
(24.1%)
United Therapeutics CorporationUTHR
1.7x
23.6%
25.7%
41.5%
BioMarin Pharmaceutical Inc.BMRN
0.6x
18.0%
139.3%
15.0%
Vertex Pharmaceuticals IncorporatedVRTX
0.2x
11.7%
N/A
(4.9%)
BioNTech SEBNTX
0.2x
(77.4%)
(89.7%)
24.4%
Royalty Pharma plcRPRX
0.1x
(3.8%)
(43.7%)
37.9%
BeiGene, Ltd.BGNE
0.0x
73.7%
467.1%
(35.9%)
Summit Therapeutics Inc.SMMT
(5.3x)
N/A
(68.7%)
N/A
OCUL key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 (100.0%) | 0.8 0.0% | 1.8 126.7% | 1.9 7.8% | 1.9 1.9% | 2.0 3.5% | 4.2 112.4% | 17.4 311.7% | 43.5 150.1% | 51.5 18.3% | 58.4 13.5% | 63.7 9.0% |
| Cost of Goods Sold (COGS) | 0.0 | 10.5 | 0.1 | 0.3 | 0.4 | 0.5 | 0.5 | 2.3 | 2.1 | 4.4 | 4.5 | 5.3 | 5.6 |
% margin | 0.0 30.0% | (10.5) 0.0% | 0.7 88.2% | 1.4 81.8% | 1.4 76.5% | 1.5 76.2% | 1.5 76.6% | 1.9 45.0% | 15.3 88.0% | 39.1 89.9% | 47.0 91.2% | 53.2 91.0% | 58.1 91.2% |
| Operating Expenses | 13.7 | 12.9 | 27.8 | 39.6 | 44.8 | 63.4 | 60.6 | 87.7 | 78.2 | 117.2 | 125.6 | 135.5 | 229.9 |
| Research & Development Expenses (R&D) | 11.5 | 10.5 | 18.9 | 26.6 | 27.1 | 30.9 | 36.9 | 41.1 | 28.7 | 50.1 | 53.5 | 61.1 | 127.6 |
| Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 8.9 | 13.0 | 17.7 | 32.5 | 23.7 | 46.6 | 49.5 | 67.1 | 72.1 | 74.5 | 102.2 |
% margin | (13.7) (136,710.0%) | (12.9) 0.0% | (27.1) (3,509.6%) | (38.2) (2,182.7%) | (43.3) (2,296.0%) | (61.9) (3,220.1%) | (59.1) (2,970.8%) | (85.8) (2,029.9%) | (62.8) (361.1%) | (78.0) (179.3%) | (78.7) (152.7%) | (82.4) (141.0%) | (171.8) (269.6%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 | 0.4 | 0.9 | 1.2 | 0.2 | 0.0 | 0.8 | 4.0 | 20.3 |
| Interest Expense | 0.4 | 0.4 | 1.1 | 1.7 | 1.7 | 1.9 | 1.7 | 6.1 | 6.8 | 6.7 | 7.0 | 11.3 | 13.6 |
| Pre-tax Income | (14.1) | (13.3) | (28.6) | (39.7) | (44.7) | (63.4) | (60.0) | (86.4) | (155.6) | (6.6) | (71.0) | (80.7) | (193.5) |
% effective tax rate | 0.3 (2.3%) | 0.5 (3.4%) | 0.1 (0.5%) | 1.0 (2.5%) | 0.8 (1.8%) | 0.3 (0.4%) | (2.3) 3.8% | 3.6 (4.1%) | 4.0 (2.6%) | 4.3 (64.9%) | (7.6) 10.7% | 0.0 0.0% | 0.0 0.0% |
% margin | (14.1) (140,930.0%) | (13.3) 0.0% | (28.6) (3,710.9%) | (39.7) (2,271.3%) | (44.7) (2,369.0%) | (63.4) (3,296.2%) | (57.7) (2,899.1%) | (89.9) (2,127.6%) | (159.6) (917.3%) | (10.8) (24.8%) | (63.4) (123.2%) | (80.7) (138.1%) | (193.5) (303.7%) |
| EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.14) | (0.83) | (1.09) | (1.22) |
| Diluted EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.13) | (0.83) | (1.02) | (1.22) |
% margin | (13.3) (133,120.0%) | (12.5) 0.0% | (27.0) (3,495.1%) | (37.3) (2,129.7%) | (42.1) (2,233.3%) | (59.9) (3,113.3%) | (56.0) (2,811.7%) | (77.7) (1,839.2%) | (146.1) (839.5%) | (75.6) (173.7%) | (61.9) (120.2%) | (66.4) (113.6%) | (176.1) (276.4%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Ocular Therapeutix, Inc.'s PEG 1Y?
As of today, Microsoft Corp's last 12-month PEG 1Y is 16.3x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual PEG 1Y for Ocular Therapeutix, Inc. have been 22.5x over the past three years, and 20.8x over the past five years.
2) Is Ocular Therapeutix, Inc.'s PEG 1Y Good?
As of today, Ocular Therapeutix, Inc.'s PEG 1Y is 16.3x, which is higher than industry median of 0.0x. It indicates that Ocular Therapeutix, Inc.'s PEG 1Y is Bad.